A Cross-Sectional Study on Socioeconomic Systems Supporting Outpatients With Parkinson’s Disease in Japan

Aiko Matsushima¹, Akihisa Matsumoto², Fumio Moriwaka³, Sanae Honma³, Kazunori Itoh⁴, Keiko Yamada⁴, Shun Shimohama⁵, Hirofumi Ohnishi¹, Junichi Matsushima⁶, and Mitsuru Mori¹

¹Department of Public Health, Sapporo Medical University School of Medicine, Sapporo, Japan
²Department of Neurology, Jozankei Hospital, Sapporo, Japan
³Hokuyukai Neurological Hospital, Sapporo, Japan
⁴Iwamizawa Neurological Medical Clinic, Iwamizawa, Hokkaido, Japan
⁵Department of Neurology, Sapporo Medical University School of Medicine, Sapporo, Japan
⁶Matsushima Oto-laryngeal and Dizziness Clinic, Sapporo, Japan

Received March 30, 2015; accepted July 8, 2015; released online December 5, 2015

ABSTRACT

Objectives: We conducted a cross-sectional study to evaluate the socioeconomic systems supporting outpatients with Parkinson’s disease (PD) in Japan.

Methods: The study was performed in 2013 at two private hospitals and one clinic in Hokkaido Prefecture, Japan. A survey was conducted with 248 consecutive PD patients, and the data from 237 PD outpatients were analyzed after excluding 11 patients who did not meet inclusion criteria. Monthly medical and transportation payments as a PD outpatient were selected as outcome variables, and their association with various explanatory variables, such as utilization of support systems for PD outpatients, were evaluated using logistic regression model analysis.

Results: After controlling for potential confounding variables, the utilization of the system providing financial aid for treatment for patients with intractable disease was significantly inversely associated with monthly medical payment among PD outpatients (OR 0.46; 95% CI, 0.22–0.95). Experience of hospital admission for PD treatment was significantly positively associated with monthly transportation payment (OR 4.74; 95% CI, 2.18–10.32). Monthly medical payment was also significantly positively associated with monthly transportation payment (OR 4.01; 95% CI, 2.23–7.51).

Conclusions: Use of Japanese public financial support systems may be associated with reductions in medical payments for PD outpatients. However, those systems may not have supported transportation payments, and higher transportation payments may be associated with an increased risk of hospitalization.

Key words: Parkinson’s disease; medical payment; cross-sectional study

INTRODUCTION

Parkinson’s disease (PD) is one of the most common progressive and disabling neurological disorders throughout the world. The prevalence of PD in Japan has been reported to be about 95 per 100,000 in 1993 in Hokkaido⁴ and 175 per 100,000 in 2005 in Kochi⁵ and is suggested to be lower in Japan than in Western countries.⁴,⁵ According to studies in Japan, the quality of life (QoL) of PD patients is lower than in the general population,⁶ and QoL decreases with increasing severity of PD.⁷ The survival rate of PD patients was also reported to be lower than that of the general population.⁸ Finding employment is difficult for PD patients because of physical impairment, and consequently, their incomes tend to be reduced,⁹ medical costs for the treatment of PD as well as for daily care tend to be relatively high.⁷,⁹ Elderly patients with PD are reported to have 84% greater total expenditures compared to those without PD in the United States.⁸ PD patients have been reported to use significantly more health care services across all categories and pay significantly more out of pocket for their medical services than other elderly individuals.⁸,⁹ PD has also been shown to have a chronic course with growing disability and considerable socioeconomic burden in Germany, as well.¹⁰
As briefly explained by Murata et al., Japan has maintained a nationwide social health insurance system based on the German social health insurance model, and Japanese citizens can receive services from any physician or hospital. Although every patient pays between 10% and 30% of the total medical charges (depending on age class as defined in the public health insurance system), more subjects with low income reported that they had stopped or postponed necessary medical care in the past year.12

In addition to the social health insurance system, there are three kinds of public financial support systems for PD patients: a system for patients with intractable diseases to receive financial aid for treatment,13 a long-term-care insurance system,14-17 and a system for patients with physical disability certificates.18 PD patients are allowed to utilize these systems depending on the stage of their illness and the degree of their disability. However, there are few studies assessing what kind of PD patients need the most financial aid and evaluating whether these three systems successfully support PD patients in receiving financial aid for medical costs and other payments related to health problems. We therefore conducted a cross-sectional study to clarify these issues in PD patients.

METHODS

The present cross-sectional study was conducted among PD outpatients from February to October in 2013 at two private hospitals and one clinic in Hokkaido Prefecture, Japan. These three medical institutions are famous for treating PD patients in Hokkaido, and each institution had at least two practicing physicians with a certificate of specialty in neurology. The inclusion criterion consisted of outpatients being treated for PD at these three medical institutions. The exclusion criteria consisted of patients who were institutionalized in a nursing home or patients being supported by the Livelihood Protection Law. Among consecutive PD outpatients of the three medical institutes, written informed consent was obtained from every participant. A structured questionnaire was completed through a face-to-face interview with a public health nurse.

The questionnaire included the following items: six items about personal characteristics, such as age, sex, working status, size of household, annual income, and body mass index (BMI; as an index for nutritional deficiency19); four items about clinical status, such as time since PD onset, time since PD diagnosis, Hoehn and Yahr stage, and degree of dysphagia (measured with 15 questions developed by Manor et al20,21); six items about medical care, such as monthly medical payments, monthly transportation payments, hospital admission for PD treatment, and utilization of the systems for patients with intractable disease receiving financial aid for treatment, long-term care insurance, and patients with physical disability certificates.

Monthly medical payments and monthly transportation payments were selected as outcome variables. In the questionnaire, both were categorized into six classes: 0 yen, <5000 yen, 5000–9999 yen, 10 000–14 999 yen, 15 000–19 999 yen, and ≥20 000 yen (currently, 1 dollar is approximately equal to 120 yen). However, we combined some classes with low frequencies and created three new classes for a more reliable analysis: 0 yen, <5000 yen, and ≥5000 yen. Similarly, the subjects were divided into three classes by monthly transportation payments: <5000 yen, 5000–9999 yen, and ≥10 000 yen.

Among the explanatory variables, age, time since PD onset, and time since PD diagnosis were categorized into two or three classes with reference to their mean values. Hoehn and Yahr stage was divided into two classes using stage 3 as a cut-off point for severity. The degree of dysphagia was also divided into two classes using a score of 11 as a cut-off point for positivity in dysphagia.20,21 BMI was categorized into three classes according to the Japanese standards of obesity: <18.5, 18.5–24.9, and ≥25.0.

Because both of the outcome variables were ordinal variables with three-level categories, univariate analysis was conducted with the Kruskal-Wallis test, and multivariable analysis was performed using the ordinal logistic model or proportional odds model22 to adjust for potential confounding variables found to have a significant relationship in the univariate analysis. Adjusted odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated using the model. The proportional odds model is reported to be derived by assuming that the outcome variable was obtained by categorizing some type of continuous variable.22 Similar to the simple logistic regression model, an obtained OR shows the strength of the association between the outcome and explanatory variables. Generally speaking, the association is thought to be relatively strong in terms of economical considerations if the OR is more than 1.5. The SAS System version 9.4 (SAS Institute, Tokyo, Japan) was utilized for these analyses. The significance level was set at 5%, and two-sided tests were conducted. This study was approved by the Institutional Review Board of Sapporo Medical University.

RESULTS

Of the 251 consecutive PD outpatients from the three medical institutes, written informed consent was obtained from 248 (98.8%). Excluding 11 patients that met the exclusion criteria, the data of 237 outpatients were analyzed. The average (standard deviation) age of the 237 PD outpatients at the time of survey and disease onset were 71.2 (8.4) years, and 62.9 (10.3) years, respectively. Among them, 83 subjects were male and 154 subjects were female (male:female ratio, 1:1.86).

Table I shows the associations of various factors with monthly medical payment divided into three classes. Time since PD onset (P = 0.013) and time since PD diagnosis (P = 0.014) were significantly inversely associated with
monthly medical payment. A Hoehn and Yahr stage \( \geq 3 \) was significantly inversely associated with monthly medical payment \( P = 0.003 \). Utilization of the system for patients with intractable disease receiving financial aid for treatment was significantly inversely associated with monthly medical payment \( P < 0.001 \). Similarly, utilization of a long-term care insurance system \( P = 0.001 \) and utilization of the system for patients with physical disability certificates \( P = 0.029 \) were significantly inversely associated with monthly medical payment. Lower annual income was significantly associated with lower monthly medical payment \( P = 0.041 \).

As shown in Table 2, even after adjusting for potential confounding variables found to have a significant relationship in the univariate analysis (see Table 1), the utilization of the system for patients with intractable disease receiving financial aid for treatment was significantly inversely associated with monthly medical payment \( \text{OR} = 0.46; 95\% \text{ CI}, 0.22–0.95 \).

Table 3 shows the associations of various factors with monthly transportation payment divided into three classes. Utilization of the system for patients with intractable disease receiving financial aid for treatment was significantly positively associated with monthly transportation payment \( P = 0.029 \). Utilization of the system for patients with physical disability certificates was significantly positively associated with monthly transportation payment \( P = 0.012 \). Likewise, hospital admission for PD treatment was significantly positively associated with monthly transportation payment \( P < 0.001 \). Monthly medical payment was significantly positively associated with monthly transportation payment \( P < 0.001 \). Other variables, such as age, sex, time since PD onset, Hoehn and Yahr stage, degree of dysphagia, and annual income, were not associated with monthly transportation payment.

Table 1. Association of various factors with monthly medical payment

| Item                                      | None | <5000 yen | \( \geq 5000 \) yen | \( P \) value<sup>a</sup> |
|-------------------------------------------|------|-----------|----------------------|--------------------------|
| Age                                       |      |           |                      |                          |
| \(< 65 \text{ years} \)                   | 5    | 20.7      | 28                   | 19.4                     | 16.0 | 26.6       | 0.607 |
| \( 65–74 \text{ years} \)                | 8    | 31.0      | 65                   | 44.5                     | 23   | 35.9       | 0.003 |
| \( \geq 75 \text{ years} \)              | 13   | 48.3      | 55                   | 36.1                     | 24   | 37.5       | 0.272 |
| Sex                                       |      |           |                      |                          |
| Male                                      | 6    | 23.1      | 53                   | 35.8                     | 24   | 38.1       | 0.014 |
| Female                                    | 20   | 76.9      | 95                   | 64.2                     | 39   | 61.9       | 0.003 |
| Time since PD onset \( < 8.0 \text{ years} \) | 10   | 38.5      | 80                   | 54.0                     | 42   | 66.7       | 0.013 |
| Time since PD diagnosis \( \geq 5.0 \text{ years} \) | 12   | 48.0      | 79                   | 53.4                     | 44   | 71.0       | 0.014 |
| Hoehn and Yahr stage \( \geq 3 \)        | 5    | 19.2      | 64                   | 43.2                     | 35   | 55.6       | 0.003 |
| Degree of dysphagia \( < 11 \)           | 18   | 69.2      | 105                  | 71.4                     | 49   | 77.8       | 0.003 |
| BMI \( < 18.5 \text{ } \text{kg/m}^2 \)   | 3    | 11.5      | 23                   | 15.5                     | 7    | 11.1       | 0.031 |
| Employed                                  |      |           |                      |                          |
| No                                        | 24   | 92.3      | 135                  | 91.2                     | 55   | 87.3       | 0.635 |
| Yes                                       | 2    | 7.7       | 13                   | 8.8                      | 8    | 12.7       | 0.480 |
| Single households                         |      |           |                      |                          |
| No                                        | 23   | 88.5      | 125                  | 84.5                     | 57   | 90.5       | 0.523 |
| Yes                                       | 3    | 11.5      | 23                   | 15.5                     | 6    | 9.5        | 0.480 |
| Utilization of system for patients with intractable disease receiving financial aid for treatment | | | | |
| None                                      | 3    | 11.5      | 43                   | 29.1                     | 31   | 49.2       | 0.001 |
| Yes                                       | 23   | 88.5      | 105                  | 70.9                     | 32   | 50.8       | 0.003 |
| Utilization of long-term care insurance system | | | | |
| None                                      | 10   | 38.5      | 80                   | 54.0                     | 46   | 73.0       | 0.001 |
| Yes                                       | 16   | 61.5      | 68                   | 46.0                     | 17   | 27.0       | 0.029 |
| Utilization of system for patients with physical disability certificate | | | | |
| None                                      | 11   | 42.3      | 98                   | 66.2                     | 45   | 71.4       | 0.179 |
| Yes                                       | 15   | 57.7      | 50                   | 33.8                     | 18   | 28.6       | 0.041 |
| Hospital admission for PD treatment | | | | |
| None                                      | 17   | 65.4      | 93                   | 62.8                     | 47   | 74.6       | 0.041 |
| Yes                                       | 9    | 34.6      | 55                   | 37.2                     | 16   | 25.4       | 0.041 |
| Annual income \( < 2.0 \text{ million yen} \) | 15   | 67.7      | 50                   | 34.7                     | 19   | 30.2       | 0.041 |
| \( 2.0–3.9 \text{ million yen} \)        | 10   | 38.5      | 72                   | 50.0                     | 30   | 47.6       | 0.041 |
| \( \geq 4.0 \text{ million yen} \)       | 1    | 3.9       | 22                   | 15.3                     | 14   | 22.2       | 0.041 |

BMI, body mass index; PD, Parkinson’s disease.
<sup>a</sup>Using the Kruskal-Wallis test.
As shown in Table 4, even after adjusting for potential confounding variables found to have a significant relationship in the univariate analysis (see Table 3), hospital admission for PD treatment was significantly positively associated with monthly transportation payment (OR 4.74; 95% CI, 2.18–10.32). Amount of monthly medical payment was also significantly positively associated with monthly transportation payment (OR 4.01; 95% CI, 2.23–7.51).

**DISCUSSION**

The system for patients with an intractable disease receiving financial aid for treatment started for PD patients in 1978, and utilization of this system was significantly inversely associated with monthly medical payment in our study, even after adjustment for potential confounding variables. This system might be effective in the reduction of payments among PD patients, especially in advanced PD patients with higher medical payments.

The Hoehn and Yahr stage has been shown to be significantly positively associated with medical expenditure in previous studies conducted outside of Japan, such as those conducted in the United Kingdom, China, Finland, the Czech Republic, Germany, and the United States. However, Hoehn and Yahr stage was inversely associated with monthly medical payment in our study in Japan, although the significance disappeared after controlling for potential confounding variables. This fact might indicate that PD patients with more severe Hoehn and Yahr stages are more...
likely to be financially supported by the public support system in Japan.

The long-term-care insurance system started in 2000, and utilization of this system was significantly inversely associated with monthly medical payment, although the significance disappeared after controlling for potential confounding variables. Because this system has been shown to be effective in increasing utilization of care services, such as frequency of nurses visiting PD patients at home, this system might be effective in reducing medical payments among PD outpatients by providing for care at home without financial conflict.

Although the system for patients with an intractable disease receiving financial aid for treatment does not support transportation costs, financial support for transportation has been provided through the system for patients with physical disability certificates. However, these reimbursements do not seem to be enough, because using this system was not associated with reduced transportation payment in this study. Further, higher transportation payment was shown to be associated with increased likelihood to be hospitalized as a PD inpatient in this study. Transportation problems have been reported to delay and discourage hospital attendance. A significantly higher frequency of transportation problems was also reported in the elderly, especially those with lower incomes. Patients who receive home oxygen therapy and patients with severe congenital heart disease have claimed that they have been mostly unsatisfied with the high costs of transportation. Since the burden of transportation payments among PD patients has been scarcely reported in Japan, further investigation is required.

Several limitations should be discussed. First, we were unable to determine a causal relationship due to the cross-sectional design. Second, our study subjects were recruited from three medical institutions in Hokkaido that are known for their quality of care in PD treatment, so their social supports for treating PD patients may be better than at other institutions. Therefore, our results may not be representative of all Japanese PD patients.

Because our data were obtained through the questionnaire, measurements of monthly medical payments as well as monthly transportation payments were not precise, but approximate. The data depended on the PD outpatient and for example, by whether they included medical payments other than PD treatments in the monthly medical payment or not, whether they included payment for taxi usage in the monthly transportation payment, and whether they answered monthly payment using an average or for a specific month. Furthermore, we did not reference medical payment records from each institution, although such a strategy would more accurately estimate the amounts of medical payments. Finally, our categorizations of the two outcome variables may not have been appropriate, because the obtained results were not uniformly distributed among the categories. Further study with a more refined study design is necessary to overcome these limitations.

In conclusion, Japanese public financial supporting systems may be associated with reduction in out-of-pocket medical payments among PD outpatients. However, the existing systems may not adequately cover transportation costs, and higher transportation payments may be associated with an increased risk of hospitalization.

**ONLINE ONLY MATERIAL**

Abstract in Japanese.

**ACKNOWLEDGMENTS**

This study was supported in part by a grant from the Health and Labor Science Research Grants from the Ministry of Health, Labour and Welfare in Japan (H26-Nanchito-Nan-Ippan-089).

Conflicts of interest: None declared.

**REFERENCES**

1. Moriwaka F, Tashiro K, Itoh K, Honma S, Okumura H, Kikuchi S, et al. Prevalence of Parkinson’s disease in Hokkaido, the northernmost island of Japan. Intern Med. 1996;35:276–9.
2. Osaki Y, Morita Y, Kuwashara T, Miyano I, Doi Y. Prevalence of Parkinson’s disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand. 2011;124:182–7.
3. Miyashita M, Narita Y, Sakamoto A, Kawada N, Akiyama M, Kayama M, et al. Health-related quality of life among community-dwelling patients with intractable neurological diseases and their caregivers in Japan. Psychiatry Clin Neurosci. 2011;65:30–8.
4. Fukunaga H, Kasai T, Yoshidome H. Clinical findings, status of care, comprehensive quality of life, daily life therapy and treatment at home in patients with Parkinson’s disease. Eur Neurol. 1997;38 Suppl 2:64–9.
5. Nakashima K, Maeda M, Tabata M, Adachi Y, Kusumi M, Ohshiro H. Prognosis of Parkinson’s disease in Japan. Eur Neurol. 1997:38 Suppl 2:60–3.
6. Huse DM, Shulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson’s disease. Mov Disord. 2005;20:1449–54.
7. Johnson S, Davis M, Kaltenboeck A, Birnbaum H, Grubb E, Tarrants M, et al. Early retirement and income loss in patients with early and advanced Parkinson’s disease. Appl Health Econ Health Policy. 2011;9:367–76.
8. Bhattacharjee S, Sambamoorthi U. Co-occurring chronic conditions and healthcare expenditures associated with Parkinson’s disease. A propensity score matched analysis. Parkinsonism Relat Disord. 2013;19:746–50.
9. Spotckke AE, Reuter M, Machat O, Bornschein B, von Campenhansen S, Berger K, et al. Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics. 2005;23:817–36.
10. Noyes K, Liu H, Holloway R, Dick AW. Economic burden associated with Parkinson’s disease on elderly beneficiaries. Mov. Disord. 2006;21:362–72.

11. Winter Y, Baizer-Geldsetzer M, Spottke A, Reese JP, Baum E, Klotsche J, et al. Longitudinal study of the socioeconomic burden of Parkinson’s disease in Germany. Eur J Neurol. 2010;17:1156–63.

12. Murata C, Yamada T, Chen C-C, Ojima T, Hirai H, Kondo K. Barrier to health care among the elderly in Japan. Int J Environ Res Publ Health. 2010;7:1330–41.

13. Taniguchi A, Narita Y, Naito H, Kasahara S. An analysis of application form of Parkinson’s disease provided by the specific diseases treatment research program of Ministry of Health, Labour and Welfare of Japan. Rinsho Shinkeigaku. 2008;48:106–13 (in Japanese with English abstract).

14. Kawai M, Oya Y, Ogawa M. The correlation between the approved level of estimated care amount in Japanese long-term care insurance and the level of disability in Parkinson’s disease. Neurol Med. 2001;55:169–73 (in Japanese with English abstract).

15. Fujii C, Masuda S. Survey on the current status of patients with Parkinson’s disease: Their lives with in-home care and the services. Nihon Kosho Eisei Zasshi. 2007;54:338–46 (in Japanese with English abstract).

16. Suketomo H, Yamaji Y, Ikeda W, Kurosawa M, Inaba Y. Changes in the use of health, medical and welfare service among patients with Parkinson’s disease: a comparison of elderly care in Japan between 2000 and 2007. Juntendo Igaku. 2008;54:344–51 (in Japanese with English abstract).

17. Ikeda W, Yamaji Y, Suketomo Y, Kurosawa M, Inaba Y. Health, medical, and welfare service utilization and related factors among patients with Parkinson’s disease. Jpn J Health Hum Ecol. 2009;75:59–65 (in Japanese with English abstract).

18. Sonoda Y, Fukunaga H. Utilization of societal resource—long-term care insurance system, physical disability certificate, care insurance—. Parkinson’s disease. Nippon Rinsho. 2009;67 Suppl 4:319–23 (in Japanese).

19. Bachmann CG, Trenkwalder C. Body weight in patients with Parkinson’s disease. Mov. Disord. 2006;21:1824–30.

20. Manor Y, Giladi N, Cohen A, Fliss DM, Cohen JT. Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson’s disease. Mov. Disord. 2007;22:1917–21.

21. Han M, Ohnishi H, Nonaka M, Yamauchi R, Hozuki T, Hayashi T, et al. Relationship between dysphagia and depressive states in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2011;17:437–9.

22. Greenland S. Introduction to regression model. In: Rothman KJ, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1998. p. 359–400.

23. Findley L, Ajula M, Bain PG, Baker M, Beech C, Bowman C, et al. Direct economic impact of Parkinson’s disease in the United Kingdom. Mov. Disord. 2003;18:1139–89.

24. Wang G, Cheng Q, Zheng R, Tan Y-Y, Sun X-K, Zhou H-Y, et al. Economic burden of Parkinson’s disease in a developing country: a retrospective cost analysis in Shanghai, China. Mov. Disord. 2006;21:1439–43.

25. Keränen T, Kaakkola S, Sotaniemi K, Laulumaa V, Haapaniemi T, Jolma T, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord. 2003;9:163–8.

26. Winter Y, von Campenhausen S, BrozoVA H, Skoupa J, Reese JP, Bötzel K, et al. Cost of Parkinson’s disease in Eastern Europe: A Czech cohort study. Parkinsonism Relat Disord. 2010;16:51–6.

27. Dodel RC, Eggert KM, Singer MS, Eichhorn TE, Pogarell O, Oertel WH. Costs of drug treatment in Parkinson’s disease. Mov. Disord. 1998;13:249–54.

28. Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnizky RL. The health burdens of Parkinson’s disease. Mov. Disord. 1998;13:406–13.

29. Hattori Y, Hattori T. Life aid and social support for patients with Parkinson’s disease. Naika. 2004;93:693 (in Japanese).

30. Shinozuka N, Mukoyama M, Ando K. Comparison between the group that keep attend hospital and the group that stop to attend hospital in chronic progressive neuromuscular disease patients. Sogoriha. 1988;16:627 (in Japanese).

31. Murata A, Takashi Y, Nakahiro K, Kaneko Y, Ito E. Does the present medical care system satisfy patients with home oxygen therapy and home therapy with assisted ventilation in Japan? Jpn J Cancer Chemother 1999;26 Suppl II:207–12 (in Japanese with English abstract).

32. Igarashi K. Support for the improvement of QOL in the adult patients with severe congenital heart disease. Iryo. 1998;52:563–6 (in Japanese with English abstract).